🧠 国际心理咨询行业简报

BetterHelp, the world's largest online therapy platform (30,000+ therapists), announced on May 14 that it is joining the Virtual Care Patient Safety & Quality Institute operated by Teladoc Health — a federally certified Patient Safety Organization. This marks the first systematic effort to establish safety event identification, risk analysis, and continuous quality improvement mechanisms in the online therapy industry. With mental health constituting 63.9% of all US telehealth claims and regulatory oversight lagging, this is seen as a landmark move toward professionalization and standardization of online therapy.

Magnus Medical announced its FDA-approved SAINT therapy for depression (non-invasive 5-day protocol, 79% remission rate, average 2.6 days to onset) has expanded to 14 states, covering top health systems including Cleveland Clinic, UPMC, HCA Healthcare, and Dartmouth-Hitchcock, with over 80 million covered lives. This neuromodulation approach is rapidly moving from academic research into mainstream clinical practice.

On April 18, President Trump signed an Executive Order to accelerate medical treatments for severe mental disorders, directing the FDA and DEA to create fast-track pathways for psilocybin, MDMA, and other psychedelic-assisted therapies. The order commits at least $50 million in federal funding, with a focus on 5-HT2A-mediated neuroplasticity mechanisms. Mental Health America welcomed the move but cautioned against self-medication.

CMS will launch the ACCESS model in July 2026, incorporating behavioral health into value-based payment for the first time. It establishes dedicated payment pathways for telehealth and digital health, creating new reimbursement routes for technology-enabled mental health services.

The HHS Secretary RFK Jr.'s federal prescription review initiative is underway, emphasizing non-pharmacological interventions including psychotherapy, exercise, and nutrition as first-line approaches. Antidepressants and pediatric psychiatric medications face stricter prescribing scrutiny. This policy direction is generating extensive debate within the psychiatric community.

The FDA approved a supplemental New Drug Application for lumateperone (42mg) for relapse prevention in schizophrenia. Phase III data showed a 63% reduction in relapse risk (HR 0.37), with 84% remaining relapse-free at 6 months. This offers a new evidence-based option for long-term schizophrenia management.

The program integrates VR exposure therapy, AI-assisted emotion regulation treatment, and specific-frequency microcurrent therapy to address the 45% increase in youth depression, anxiety, and suicide attempts since the pandemic. This multi-technology IOP model represents an innovative direction for youth mental health services.

The global digital mental health market reached $39.04 billion in 2026 and is projected to reach $151.81 billion by 2034 (CAGR 18.5%). M&A activity remains robust: Teladoc acquired UpLift, Spring Health acquired Alma, and Universal Health Services acquired Talkspace for approximately $835 million. The market is consolidating rapidly.